Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A pre-existing coordinated inflammatory microenvironment is associated with complete response of vulvar high-grade squamous intraepithelial lesions to different forms of immunotherapy.
Abdulrahman Z, de Miranda NFCC, Hellebrekers BWJ, de Vos van Steenwijk PJ, van Esch EMG, van der Burg SH, van Poelgeest MIE. Abdulrahman Z, et al. Among authors: van poelgeest mie, van der burg sh, van esch emg. Int J Cancer. 2020 Nov 15;147(10):2914-2923. doi: 10.1002/ijc.33168. Epub 2020 Jul 3. Int J Cancer. 2020. PMID: 32574376 Free PMC article.
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH. Smyth LJ, et al. Clin Cancer Res. 2004 May 1;10(9):2954-61. doi: 10.1158/1078-0432.ccr-03-0703. Clin Cancer Res. 2004. PMID: 15131030 Clinical Trial.
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH. van Poelgeest MI, et al. Clin Cancer Res. 2005 Jul 15;11(14):5273-80. doi: 10.1158/1078-0432.CCR-05-0616. Clin Cancer Res. 2005. PMID: 16033846 Free article. Clinical Trial.
Preoperative predictors of postsurgical adhesion formation and the Prevention of Adhesions with Plasminogen Activator (PAPA-study): results of a clinical pilot study.
Hellebrekers BW, Trimbos-Kemper TC, Boesten L, Jansen FW, Kolkman W, Trimbos JB, Press RR, van Poelgeest MI, Emeis SJ, Kooistra T. Hellebrekers BW, et al. Fertil Steril. 2009 Apr;91(4):1204-14. doi: 10.1016/j.fertnstert.2008.01.052. Epub 2008 Mar 18. Fertil Steril. 2009. PMID: 18353314 Free article. Clinical Trial.
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia.
van den Hende M, van Poelgeest MI, van der Hulst JM, de Jong J, Drijfhout JW, Fleuren GJ, Valentijn AR, Wafelman AR, Slappendel GM, Melief CJ, Offringa R, van der Burg SH, Kenter GG. van den Hende M, et al. Int J Cancer. 2008 Jul 1;123(1):146-52. doi: 10.1002/ijc.23502. Int J Cancer. 2008. PMID: 18404684 Free article.
81 results